Novel glaucoma shunt breakthrough
Seattle, Wash. — One study presented this week at the 2024 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) introduced a new type of shunt for treating glaucoma that can be adjusted after surgery to control how much fluid flows out of the eye. This novel shunt could potentially improve postoperative intraocular pressure (IOP) control and lower the risk of vision-threatening issues.
Ariana Levin, MD, from New York University, along with team members from Myra Vision in California and the John A. Moran Eye Center in Utah, present a novel shunt that can be opened or closed using a laser.
Levin said they developed “a novel titratable aqueous shunt for glaucoma therapy designed to allow physicians to increase or decrease the flow of aqueous fluid through the shunt in a slit lamp-based laser procedure. The potential to control aqueous fluid in the postoperative period may allow physicians to personalize care for every patient and potentially improve the safety and efficacy of glaucoma surgery.”
- Abstract title: A novel glaucoma shunt allows for titratable flow after implantation
- Presentation start/end time: Monday, May 6, 4 – 4:15pm PT
- Location: Room 608 (Level 6), Seattle Convention Center – Arch Building
- Presentation number: 2129
##
The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include approximately 10,000 eye and vision researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. Learn more at ARVO.org.
Media contact:
Jenniffer Scherhaufer, MMC, CAE
1.240.221.2923
media@arvo.org